SOLARA logo

Solara Active Pharma Sciences Limited Stock Price

NSEI:SOLARA Community·₹27.0b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 9 Fair Values set on narratives written by author

SOLARA Share Price Performance

₹560.40
-122.05 (-17.88%)
₹566.00
Fair Value
₹560.40
-122.05 (-17.88%)
1.0% undervalued intrinsic discount
₹566.00
Fair Value
Price ₹560.40
AnalystConsensusTarget ₹566.00

SOLARA Community Narratives

AnalystConsensusTarget·
Fair Value ₹566 1.0% undervalued intrinsic discount

FDA Approvals And Rising API Demand Will Drive Margin Expansion Over The Long Term

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
₹566
1.0% undervalued intrinsic discount
Revenue
29.39% p.a.
Profit Margin
18.48%
Future PE
8.81x
Price in 2028
₹802.67

Trending Discussion

Updated Narratives

SOLARA logo

FDA Approvals And Rising API Demand Will Drive Margin Expansion Over The Long Term

Fair Value: ₹566 1.0% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with high growth potential.

2 Risks
4 Rewards

Solara Active Pharma Sciences Limited Key Details

₹12.1b

Revenue

₹5.9b

Cost of Revenue

₹6.2b

Gross Profit

₹6.1b

Other Expenses

₹64.1m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
1.33
51.27%
0.53%
49.6%
View Full Analysis

About SOLARA

Founded
2017
Employees
1775
CEO
Sandeep Rao
WebsiteView website
www.solara.co.in

Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immune-suppressant, loop diuretic, NSAIDs, anti-hyperkalaemia, nucleoside inhibitor, OAB treatment, phenylalanine reducer, phosphate binder, reversal of neuro-muscular blocking agent, skeletal muscle relaxant, and topical anti-infectives. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical development, impurity synthesis, and regulatory support. In addition, the company exports its products. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.

Recent SOLARA News & Updates

Calculating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Dec 10
Calculating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Recent updates

No updates